Fatigue and myalgia in AIDS patients

Area of Science:

• Exercise physiology
• Muscle metabolism
• Immunology

Background:

• Fatigue and myalgia are prevalent symptoms in patients with acquired immunodeficiency syndrome (AIDS).
• These symptoms can significantly impact patient quality of life and treatment adherence.
• Azidothymidine (AZT), a common antiretroviral medication, is suspected to cause mitochondrial myopathy, contributing to muscle symptoms.

Purpose of the Study:

• To investigate whether altered muscle metabolism or impaired muscle activation contribute to fatigue and myalgia in AIDS patients.
• To determine if azidothymidine (AZT) therapy is associated with mitochondrial myopathy in this patient population.

Main Methods:

• Nine AIDS patients experiencing fatigue and myalgia underwent three exercise protocols to induce fatigue.
• Simultaneous measurements of muscle force, electromyography (EMG), and muscle metabolites (using phosphorus nuclear magnetic resonance spectroscopy) were recorded during exercise and recovery.
• Data from patients were compared to healthy controls.

Main Results:

• No significant differences were observed between AIDS patients and controls in fatigability, muscle metabolism, or muscle activation.
• Specific muscle metabolites, including phosphocreatine, inorganic phosphate, adenosine triphosphate, and intracellular pH, showed no significant alterations attributable to the disease or AZT treatment.
• The study found no evidence supporting AZT-induced mitochondrial myopathy.

Conclusions:

• The findings do not support the hypothesis that fatigue or myalgia in AIDS patients stem from altered muscle metabolism or impaired muscle activation.
• Azidothymidine (AZT) does not appear to cause mitochondrial myopathy in the context of AIDS.
• Further research may be needed to explore other potential causes of fatigue and myalgia in AIDS patients.